Gonadotropin‐releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study

Chou, Yi-Sheng; Wang, Chun‐Chieh; Hsu, Li-Fei; Chuang, Pei-Hung; Cheng, Chi-Feng; Li, Naihsin; Chen, Chu-Chieh; Chen, Chien-Liang; Lai, Yun‐Ju; Yen, Yung‐Feng

doi:10.1002/cam4.5390

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of GnRH agonists on ischemic heart disease has not been established, but some authors report an increased risk of cardiovascular toxicity after treatment with GnRH agonists, especially in men with prostate cancer [ 113 , 114 ], whereas it has not been demonstrated in women with BC. A recent study found that female patients with breast cancer receiving GnRH agonists had a lower risk of developing ischemic heart disease than patients not receiving them [ 115 ].…”

Section: Breast Cancer Therapiesmentioning

confidence: 99%

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta

Ceramella

Baldino

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of cancer death among women worldwide. Globally, BC is the second most frequent cancer and first most frequent gynecological one, affecting women with a relatively low case-mortality rate. Surgery, radiotherapy, and chemotherapy are the main treatments for BC, even though the latter are often not aways successful because of the common side effects and the damage caused to healthy tissues and organs. Aggressive and metastatic BCs are difficult to treat, thus new studies are needed in order to find new therapies and strategies for managing these diseases. In this review, we intend to give an overview of studies in this field, presenting the data from the literature concerning the classification of BCs and the drugs used in therapy for the treatment of BCs, along with drugs in clinical studies.

show abstract

Section: Breast Cancer Therapiesmentioning

confidence: 99%

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta

Ceramella

Baldino

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…However, despite the pathophysiological mechanisms mentioned above, in female patients evidence is scarce and controversial. An observational study conducted on 172,850 female patients with breast cancer found that use of GnRH agonists was associated with a reduced risk of ischemic heart disease (HR: 0.50; 95% CI: 0.39-0.64) [72]. However, this analysis did not take into account the concomitant or sequential administration of adjunctive medications that could have influenced outcomes, especially considering that the study comprised cases ranging from 2000 to 2018.…”

Section: Gnrh Analogues and Cardiovascular Outcomes: Ischemic Heart D...mentioning

confidence: 99%

Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease

Bergami,

Manfrini,

Cenko

et al. 2023

JCM

View full text Add to dashboard Cite

The combination of classic chemotherapy agents like anthracyclines with novel targeted medications has had a positive impact on women’s survival from breast cancer. GnRH analogues are primarily employed to temporarily suppress ovarian function in premenopausal women with hormone-receptor-positive (HR+) breast cancer. Despite their benefits, the true degree of their collateral effects has been widely understudied, especially when it comes to ischemic heart disease. This review aims at summarizing the current state of the art on this issue, with particular focus on the risk for cardiotoxicity associated with the combined use of GnRH analogues and anthracyclines.

show abstract